Dimeric bacteriophage lysins
AssigneeThe Rockefeller University
InventorsVincent A. Fischetti, Gregory Resch
Life of this patent
Estimating the term…
Abstract
The present invention provides isolated dimeric Streptococcus-specific phage lysins having two Streptococcus-specific phage lysin monomers covalently linked to each other, and having killing activity against one or more Streptococcus bacteria. Also provided for are pharmaceutical compositions of dimeric lysins and their use in therapeutic treatment or alleviation of infections or bacterial colonizations. The dimeric lysins may also be used to decontaminate porous and non-porous surfaces or devices.
Claims20
An isolated dimeric phage lysin comprising two phage lysin monomers specific for bacteria and capable of killing at least one or more Streptococcus bacteria covalently linked to each other, wherein said dimer has killing activity against one or more Streptococcus bacteria that is greater than the killing activity of any one of the phage lysin monomers, and wherein the lysin monomers are covalently associated or cross-linked via reactive groups or via amino acids in each monomer sequence at the C-terminus.
Dependencies are inferred from the claim text.